Another successful example of the implementation of molecular docking studies using MOE is represented by the discovery of Azelnidipine (Compound 8, Figure 3) as a dual inhibitor of TIGIT/PVR and CD47/SIRPα along with the demonstration of the significant inhibition of the growth of CT26 tumors in vivo by Azelnidipine based on enhancing the infiltration and function of the CD8+ T cell in the tumor [58]. Here, CD8A is linked to neoplasm.